H.M. Pharma Consultancy would like to alert you to the availability of a new peer-review paper to which the entire core team has contributed:
Mucke HAM*, Mucke P & Mucke E.
Pharmacological therapies for cataract and refractive errors: landscaping niches of ocular drug patenting.Pharm. Pat. Analyst (2012) 1(2), 165–175 [Abstractand free PDF downloads]
You might also want to visit the Pharmaceutical Patent Analyst website, and catch a glimpse of all the other papers that have so far appeared in this new journal. This includes our regular patent reviews which will continue to be published in future issues of this exciting new product.
Remember our blog posts discussing our THIRDSPACE patent database project and its ocular pilot module, REDWING — as for example, here? The idea is to identify every single unique patent document relevant to ocular developments that was ever published, and to unleash the full potential of this collection by providing correct fulltext, PubMed-like indexing, hyperlinking, and comments. This database has grown to cover 5,200 documents from all areas of ocular pharmacology, biotechnology, and biomarker diagnostics. Almost three quarters of these documents — at this precise time, 153,300 pages of text, tables and figures — have been OCRed and corrected for software recognition errors.
Just as our earlier invited review, “Current drug patenting for retinal diseases: Beyond VEGF inhibitors”(Mucke H & Mucke P, IDrugs (2010) 13(1):30-37 [PubMed entry]) the newest paper highlights an aspect of what we can do with this emerging database — in this particular application, patent landscaping. (If you want to know if some idea you have might be patentable, we can serve your needs with a very quick turnaround time.) This time, we cover an area of ocular therapy which is not usually thought of as amenable to pharmacological therapy. But science and technology advance everywhere. We believe this paper makes a quite impressive reading because the landscape which it paints is more than a snapshot; it includes time (from 1982 to 2011) as a dimension, showing how the focus and the approaches of industry and academic patenting has shifted and evolved over the past three decades.